Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Vassilis, Atsaves"'
Autor:
L. J. Medeiros, Dan Grandér, Vasiliki Leventaki, Theocharis Panaretakis, Dimitris Chioureas, Vassilis Atsaves, Nikolaos Tsesmetzis, Loránd L. Kis, Ken H. Young, Elias Drakos, George Z. Rassidakis
Publikováno v:
Leukemia. 31(7)
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
Autor:
Dan Jones, L. Jeffrey Medeiros, Chryssoula Liakou, Efstratios Patsouris, Elias Drakos, Lazaros Lekakis, Vasiliki Leventaki, George E. Baltatzis, Dimitris Chioureas, George Z. Rassidakis, Marianna Feretzaki, Francois Xavier Claret, Mehran Ghaderi, Panayiotis Panayiotidis, Vassilis Atsaves, Vassilis G. Gorgoulis
Publikováno v:
British Journal of Haematology. 167:514-523
Anaplastic lymphoma kinase (ALK)+ anaplastic large cell lymphoma (ALCL) frequently carries the t(2;5)(p23;q35) resulting in expression of NPM1(NPM)-ALK oncogenic kinase. The latter is capable of activating ERK kinase, which upregulates JUNB expressio
Autor:
Ioannis Tsironis, George Vassilopoulos, Margarita Gkyzi, Emmanouil Simantirakis, Vassilis Atsaves, Kostas Konstantopoulos
Publikováno v:
Blood. 134:4646-4646
Introduction A novel approach that can cover the therapeutic gap in NHL treatment are the autologous T cells, expressing Chimeric Antigen Receptors (CAR-T cells) against tumor markers. Such clinical-grade products based on Lenti (LV) or Retro- vector
Autor:
Georgios Z. Rassidakis, Elias Drakos, Anders Österborg, Vassilis Atsaves, Georgia Kokaraki, Francois X. Claret, Konstantina Stathopoulou, P. Farrajota Neves da Silva, L. J. Medeiros
Publikováno v:
HemaSphere. 3:596
Autor:
Nikolaos Roidis, Vassilis Atsaves, Anastasios E. Germenis, George Z. Rassidakis, Vasiliki Leventaki, Kostantinos Tepetes, Paraskevi Liakou, Konstantinos Hatzitheophilou, Efstratios Patsouris
Publikováno v:
Journal of Surgical Oncology. 105:643-649
Background and Objectives Endothelin-1 (ET-1), a potent vasoconstricting peptide, plays an important role in carcinogenesis. Previous in vitro studies have shown that colorectal cancer cells produce ET-1. Methods ET-1 and its receptors ET-A (ETAR) an
Autor:
Nikolaos Tsesmetzis, Vassilis Atsaves, Georgia Kokaraki, Pedro Farrajota Neves Da Silva, Anders Österborg, George Z. Rassidakis
Publikováno v:
Blood. 132:2868-2868
Introduction: The PD-1 / PD-L1 interaction is a crucial immune checkpoint in cancer, which has been targeted by monoclonal antibodies currently used in clinical trials. The genetic basis and transcriptional regulation of PD-L1 has been previously inv
Autor:
Vasiliki Leventaki, Dan Jones, Ellen J. Schlette, Athina Vidaki, Claudiu V. Cotta, George Z. Rassidakis, Vassilis Atsaves, L. Jeffrey Medeiros
Publikováno v:
Cancer. 112:552-561
BACKGROUND. Inhibitor of DNA binding 2 (Id2), a helix-loop-helix protein of the inhibitor of differentiation (ID) family, is involved in hematopoiesis, mainly through interaction with the E-family of transcription factors. Recent studies have shown t
Autor:
Paraskevi, Liakou, Kostantinos, Tepetes, Anastasios, Germenis, Vasiliki, Leventaki, Vassilis, Atsaves, Efstratios, Patsouris, Nikolaos, Roidis, Konstantinos, Hatzitheophilou, George Z, Rassidakis
Publikováno v:
Journal of surgical oncology. 105(7)
Endothelin-1 (ET-1), a potent vasoconstricting peptide, plays an important role in carcinogenesis. Previous in vitro studies have shown that colorectal cancer cells produce ET-1.ET-1 and its receptors ET-A (ET(A) R) and ET-B (ET(B) R) were analyzed i
Autor:
L J Medeiros, Vassilis Atsaves, Ellen J. Schlette, I Papanastasi, Georgios Z. Rassidakis, Elias Drakos, Jiang Li
Publikováno v:
Leukemia. 23(12)
p53 is expressed frequently, but is rarely mutated in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) tumours. Nutlin-3a is a recently developed small molecule that targets Mdm2, a critical negative regulator of p53, a
Autor:
L. J. Medeiros, Vasiliki Leventaki, M. Andreeff, Vassilis Atsaves, Elias Drakos, Jiang Li, Georgios Z. Rassidakis
Publikováno v:
Leukemia. 23(4)
Mantle cell lymphoma (MCL) is a clinically aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13;q32) and overexpression of cyclin D1. A high proportion of MCL tumors harbor wild-type (wt) and potentially functional p53 gene. We sh